# mCRPC FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/mcrpc

> No upcoming FDA catalysts in mCRPC; 5 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for mCRPC?

No upcoming FDA catalysts in mCRPC; 5 past events are recorded. Press release filed with the SEC (EX-99): "Topline results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected to be presented at a medical conference in 1Q 2026" [Calendar and source filings](https://sec-api.dev/indications/mcrpc)

Source: Press release filed with the SEC (EX-99), accession 0001193125-25-274192, https://www.sec.gov/Archives/edgar/data/921299/000119312525274192/fgen-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-01-07. Cite: https://sec-api.dev/indications/mcrpc#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2024 | [FG-3246 interim data readout](https://sec-api.dev/pdufa/fg-3246) | KYNB | mCRPC | completed, positive | "In May 2024, the University of California, San Francisco ("UCSF") presented positive interim results from the dose escalation portion of the investigator-sponsored Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with mCRPC at the 2024 American Society of Clinical Oncology Annual Meeting." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/921299/000119312525274241/fgen-20250930.htm)) |
| Q1 2025 | [FG-3246 trial start](https://sec-api.dev/pdufa/fg-3246) | KYNB | mCRPC | scheduled | "Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC anticipated in 1Q 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/fgen-ex99_1.htm)) |
| 1H 2025 | [FG-3246 topline data readout](https://sec-api.dev/pdufa/fg-3246) | KYNB | mCRPC | scheduled | "Topline results from the Phase 2 portion of the investigator-sponsored Phase 1b/2 study conducted by UCSF of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 1H 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/fgen-ex99_1.htm)) |
| Q4 2025 | [FG-3246 topline data readout](https://sec-api.dev/pdufa/fg-3246) | KYNB | mCRPC | scheduled | "Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 4Q 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000095017025069159/fgen-ex99_1.htm)) |
| Q1 2026 | [FG-3246 topline data readout](https://sec-api.dev/pdufa/fg-3246) | KYNB | mCRPC | scheduled | "Topline results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected to be presented at a medical conference in 1Q 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000119312525274192/fgen-ex99_1.htm)) |

## Drugs

- [FG-3246](https://sec-api.dev/pdufa/fg-3246) (KYNB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/mcrpc.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "mCRPC FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/mcrpc

```bibtex
@misc{secapidev_indications_mcrpc_20261116,
  title        = {mCRPC FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/mcrpc}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_mcrpc_20261116","title":"mCRPC FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/mcrpc","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
